29F.1A12™-CP004單克隆抗體是原始29F.1A12™克隆號的重組嵌合型抗體。可變結構域序列與原始29F.1A12™克隆號相同,但是恒定區序列已經從大鼠IgG2a變為小鼠IgG1。29F.1A12™-CP004抗體像原始大鼠IgG2a抗體一樣無Fc突變。
29F.1A12™-CP004單克隆抗體與小鼠PD-1(程序性死亡-1蛋白,也稱為CD279)反應。PD-1是一種50-55 kDa的細胞表面受體,由Pdcd1基因編碼,屬于免疫球蛋白超家族的CD28家族。PD-1在CD4和CD8胸腺細胞以及活化的T和B淋巴細胞和骨髓細胞上瞬時表達。成功清除抗原后,PD-1表達下降。此外,Pdcd1 mRNA在前B細胞階段發育中的B淋巴細胞中表達。PD-1的結構包括一個ITIM(免疫受體酪氨酸抑制基序),表明PD-1負調節TCR信號。PD-1通過結合它的兩個配體PD-L1和PD-L2發出信號,這兩個配體都是B7家族的成員。配體結合后,PD-1信號抑制T細胞活化,導致增殖、細胞因子產生和T細胞死亡減少。此外,已知PD-1在小鼠的外周耐受性和預防自身免疫性疾病中起關鍵作用,因為PD-1敲除動物表現出擴張性心肌病、脾腫大和外周耐受性喪失。誘導的PD-L1表達常見于許多腫瘤,包括鱗狀細胞癌、結腸腺癌和乳腺腺癌。PD-L1過度表達導致腫瘤細胞對CD8 T細胞介導的裂解的抗性增加。在黑色素瘤的小鼠模型中,通過用阻斷PD-L1和它的受體PD-1之間的相互作用,腫瘤生長可以暫時被抑制。目前PD-1是癌癥免疫療法的熱門靶點之一。
產品詳情:
產品名稱 | RecombiMAb anti-mouse PD-1 (CD279) |
產品貨號 | CP004 |
產品規格 | 1mg |
反應種屬 | Mouse |
克隆號 | 29F.1A12™-CP004 |
同種型 | Mouse IgG1(switched from rat IgG2a) |
免疫原 | Recombinant PD-1-Ig fusion protein |
實驗應用 | in vivo blocking of PD-1/PD-L signaling* in vitro PD-1 neutralization* Immunohistochemistry (frozen)* Immunofluorescence* Western blot* Flow cytometry* *Reported for the original rat IgG2a 29F.1A12 antibody |
產品形式 | PBS, pH 7.0,Contains no stabilizers or preservatives |
純度 | >95%, Determined by SDS-PAGE |
聚合 | <5%, Determined by SEC |
無菌處理 | 0.2 µm filtration |
純化方式 | Protein G |
分子量 | 150 kDa |
小鼠病原檢測 | Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative |
保存條件 | 抗體原液保存在4°C,不能冷凍保存。 |
推薦同型對照 | InVivoPlus mouse IgG1 isotype control, unknown specificity(貨號BP0083) |
推薦抗體稀釋液 | InVivoPure pH 7.0 Dilution Buffer(貨號IP0070) |
該產品自上市已被多篇SCI文獻引用,品質有保證,以下是部分已發表的文獻引用:
應用 | 文章 |
體內PD-1/PD-L信號阻斷 (in vivo blocking of PD-1/ PD-L signaling) | 1. Wang, W., et al. (2018). 'RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer' Cancer Cell 34(5): 757-774 e757. 2. Gordon, S. R., et al. (2017). 'PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity' Nature 545(7655): 495-499. 3. Koyama, S., et al. (2016). 'STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment' Cancer Res 76(5): 999-1008. |
體內PD-1/PD-L信號阻斷, 流式細胞術 (in vivo blocking of PD-1/ PD-L signaling, Flow Cytometry) | 1.Koyama, S., et al. (2016). 'Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints' Nat Commun 7: 10501. |
體外PD-1中和 (in vitro PD-1 neutralization) | 1.Park, S. J., et al. (2014). 'Negative role of inducible PD-1 on survival of activated dendritic cells' J Leukoc Biol 95(4): 621-629. |
體內PD-1/PD-L信號阻斷, 體外PD-1中和(in vivo blocking of PD-1/PD-L signaling, in vitro PD-1 neutralization) | 1.Duraiswamy, J., et al. (2013). 'Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors' Cancer Res 73 (12): 3591-3603. |
流式細胞術 (Flow Cytometry) | 1.Good-Jacobson, K. L., et al. (2012). 'CD80 expression on B cells regulates murine T follicular helper development, germinal center B cell survival, and plasma cell generation' J Immunol 188(9): 4217-4225. |
更多產品詳情請聯系BioXCell 中國授權代理——欣博盛生物
請輸入賬號
請輸入密碼
請輸驗證碼
以上信息由企業自行提供,信息內容的真實性、準確性和合法性由相關企業負責,化工儀器網對此不承擔任何保證責任。
溫馨提示:為規避購買風險,建議您在購買產品前務必確認供應商資質及產品質量。